Fujian Haixi Pharmaceuticals Co (HKSE:02637) GF Score: 23/100 (As of Aug. 16, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02637 Fujian Haixi Pharmaceuticals Co Ltd HKSE:02637
23 GF Score
Price HK$204.80
! 2 Warning Signs
View Full Analysis

What is Fujian Haixi Pharmaceuticals Co GF Score?

Fujian Haixi Pharmaceuticals Co HKSE:02637 +3.28% 23 GF Score is 23 as of Aug. 16, 2026, which is at its 10-year median of 23.00. GuruFocus rates HKSE:02637 with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Fujian Haixi Pharmaceuticals Co has the GF Score of 23, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 9/10
2. Profitability Rank : 6/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Fujian Haixi Pharmaceuticals Co might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Fujian Haixi Pharmaceuticals Co  (HKSE:02637) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Fujian Haixi Pharmaceuticals Co GF Score Related Terms

HKSE:02637 vs ZTS: GF Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Fujian Haixi Pharmaceuticals Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fujian Haixi Pharmaceuticals Co GF Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fujian Haixi Pharmaceuticals Co's GF Score distribution charts can be found below:

* The bar in red indicates where Fujian Haixi Pharmaceuticals Co's GF Score falls into.


HKSE:02637
23GF Score
Fujian Haixi Pharmaceuticals Co Ltd HKSE:02637
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 23 mean?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a GF Score of 23 as of Aug. 16, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. This is near median its historical median of 23.00. Over the past decade, Fujian Haixi Pharmaceuticals Co's GF Score has ranged from 20.00 to 26.00.
Is Fujian Haixi Pharmaceuticals Co's GF Score too high?
Fujian Haixi Pharmaceuticals Co's current GF Score of 23 is near median its 10-year median of 23.00. Over the past 10 years, this metric has ranged from a low of 20.00 to a high of 26.00. Overall, Fujian Haixi Pharmaceuticals Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Fujian Haixi Pharmaceuticals Co's GF Score compare to ZTS?
Fujian Haixi Pharmaceuticals Co's GF Score of 23 can be compared against companies in the Drug Manufacturers industry. Historically, Fujian Haixi Pharmaceuticals Co's own GF Score has ranged from 20.00 to 26.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. Fujian Haixi Pharmaceuticals Co's current GF Score is 23, which is near median its own 10-year median of 23.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Haixi Pharmaceuticals Co stock overvalued right now?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a current GF Score of 23. The current GF Score is 23, which is near median its 10-year median of 23.00. Fujian Haixi Pharmaceuticals Co's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Fujian Haixi Pharmaceuticals Co (HKSE:02637), the current GF Score is 23 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Fujian Haixi Pharmaceuticals Co Business Description

Address No. 177 Jinda Road, Floor 3rd & 4th, Block B, Jianxin Town, Cangshan District,Fujian Province, Fuzhou, CHN, 350028
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
23GF Score

Get the complete analysis for HKSE:02637

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$204.80
Price